BetterLife Obtains Favourable Animal Safety Data for Repeated Oral Dosing of BETR-001
12 Septiembre 2023 - 7:00AM
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR
/ OTCQB: BETRF / FRA: NPAU), an emerging biotech company
focused on the development of BETR-001, a non-hallucinogenic
derivative of lysergic acid diethylamide (“LSD”), announced it has
completed its 4-week oral BETR-001 GLP toxicology study in animals.
The study demonstrated that BETR-001’s repeated dosing for 4 weeks
is very well-tolerated. The study findings support a broad
therapeutic window for the use of BETR-001 in humans.
Dr. Ahmad Doroudian, CEO of BetterLife
commented, “BETR-001 is a unique non-hallucinogenic derivative of
LSD, which we have shown has robust activity in animal depression
and anxiety models without the burden of being hallucinogenic. We
are very pleased with the results of this GLP toxicology study of
oral BETR-001 in vivo. The study shows that BETR-001, even with
repeat dosing at high doses, is very well tolerated. These data
predict that BETR-001 will have a broad therapeutic window in
humans; that is, BETR-001 dosing at levels that are effective is
predicted to not have unwanted side effects. Given BETR-001’s
non-hallucinogenic characteristics, this means that BETR-001 will
have a significant advantage over other compounds being developed
in this field, whether psychedelics or derivatives thereof. These
data, together with the other ongoing IND-enabling nonclinical
toxicology studies, will support the filing of BETR-001’s IND
application with the FDA and initiation of human clinical
trials.”
About BetterLife Pharma
BetterLife Pharma Inc. is an emerging
biotechnology company primarily focused on developing and
commercializing two compounds, BETR-001 and BETR-002, to treat
neuro-psychiatric and neurological disorders.
BETR-001, which is in preclinical and
IND-enabling studies, is a non-hallucinogenic and non-controlled
LSD derivative in development and it is unique in that it is
unregulated and therefore can be self-administered. BetterLife’s
synthesis patent for BETR-001 eliminates regulatory hurdles and its
pending patent, for composition and method of use, covers treatment
of major depressive disorder, anxiety disorder and neuropathic pain
and other neuro-psychiatric and neurological disorders.
BETR-002, which is in preclinical and
IND-enabling studies, is based on honokiol, the active anxiolytic
ingredient of magnolia bark. BetterLife’s pending method of use and
formulations patent covers treatment of anxiety related disorders
including benzodiazepine dependency.
BetterLife also owns a drug candidate for the
treatment of viral infections such as COVID-19 and is in the
process of seeking strategic alternatives for further
development.
For further information, please
visit BetterLife Pharma.
ContactDavid Melles, Investor
Relations Manager Email: David.Melles@blifepharma.comPhone:
1-778-887-1928
Cautionary Note Regarding
Forward-Looking Statements
No securities exchange has reviewed nor accepts
responsibility for the adequacy or accuracy of the content of this
news release. This news release contains forward-looking statements
relating to product development, licensing, commercialization and
regulatory compliance issues and other statements that are not
historical facts. Forward-looking statements are often identified
by terms such as “will”, “may”, “should”, “anticipate”, “expects”
and similar expressions. All statements other than statements of
historical fact, included in this release are forward-looking
statements that involve risks and uncertainties. There can be no
assurance that such statements will prove to be accurate and actual
results and future events could differ materially from those
anticipated in such statements. Important factors that could cause
actual results to differ materially from the Company’s expectations
include the failure to satisfy the conditions of the relevant
securities exchange(s) and other risks detailed from time to time
in the filings made by the Company with securities regulations. The
reader is cautioned that assumptions used in the preparation of any
forward-looking information may prove to be incorrect. Events or
circumstances may cause actual results to differ materially from
those predicted, as a result of numerous known and unknown risks,
uncertainties, and other factors, many of which are beyond the
control of the Company. The reader is cautioned not to place undue
reliance on any forward-looking information. Such information,
although considered reasonable by management at the time of
preparation, may prove to be incorrect and actual results may
differ materially from those anticipated. Forward-looking
statements contained in this news release are expressly qualified
by this cautionary statement. The forward-looking statements
contained in this news release are made as of the date of this news
release and the Company will update or revise publicly any of the
included forward-looking statements as expressly required by
applicable law.
BetterLife Pharma (TG:NPAU)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
BetterLife Pharma (TG:NPAU)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024